2016 - earlier

Selected News from the Archive 2008-2010

16 December 2010

Neurotune wins the third place in the 2010 Eurecan European Venture Contest (EEVC) finals in the category healthcare companies. The finalists were selected by an international jury out of 987 applications from 24 countries.

21 October 2010

Neurotune announces positive top-line Phase IIa results for dimiracetam to treat neuropathic pain in HIV patients
Neurotune AG, a Swiss biopharmaceutical company, today announced positive top-line results from its phase IIa, safety and tolerability, study of dimiracetam (NT-11624), its lead compound for treatment-induced neuropathic pain in HIV patients receiving anti-retroviral medication.

17 August 2009

Neurotune announces regulatory approval for Phase II Clinical Trial to treat neuropathic pain in HIV patients
Neurotune AG has received MCC ’s (the South African National Regulatory Agency) approval for a Phase II clinical study of Neurotune’s lead compound NT-11624 for neuropathic pain caused by treatment with anti-retroviral medication.

15 January 2009

Neurotune successfully completes Phase I Trials with its Lead Compund NT-11624
Neurotune AG, a Swiss biopharmaceutical company, which has recently acquired two programs in neuropathic pain, announces the successful completion of Phase I for its lead compound NT-11624 developed for treatment of neuropathic and osteoarthritic pain. NT-11624, dimiracetam, is a selective small molecular NMDA-receptor antagonist, which acts on a new site of the receptor.

18 September 2008

Neurotune expands its portfolio by acquiring neuropathic pain projects
Neurotune AG announces that the shareholders meeting, held on August 29th 2008, approved of the expansion of its portfolio with two programs in neuropathic pain. The company has reached an agreement with the Italy-based company Brane Discovery Srl. to acquire rights for two programs in neuropathic pain in a combined cash and share transaction.

29 July 2008

Neurotune completes next funding round
Neurotune AG announces the closing of the fourth funding round. Another single-digit million Swiss francs will accrue to the company. The company will use the increase in capital to advance the development of its therapeutical approach to treat sarcopenia and along with this the diagnostical methods. Part of the capital will be used to extend a developmental pipeline.

19 June 2007

Neurotune AG is honoured on the occasion of the award ceremony „ZKB Pioneer Award TECHNOPARK® 2007“
Neurotune AG was awarded a prize for its activity in the area of developing drugs to treat age-related muscle atrophy – Sarcopenia – and other disorders of the human nervous system on Tuesday evening.